• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

化疗引起的口服化疗治疗儿童急性淋巴细胞白血病的恶心和呕吐:可行性研究。

Chemotherapy-induced nausea and vomiting from oral chemotherapy for childhood acute lymphoblastic leukaemia: feasibility study.

机构信息

Pharmacy, The Hospital for Sick Children, Toronto, Ontario, Canada.

Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.

出版信息

BMJ Support Palliat Care. 2022 Nov;12(e5):e646-e649. doi: 10.1136/bmjspcare-2019-002022. Epub 2019 Nov 29.

DOI:10.1136/bmjspcare-2019-002022
PMID:31784465
Abstract

OBJECTIVE

To evaluate the feasibility of a large prospective trial aimed at improving chemotherapy-induced nausea and vomiting (CINV) control in paediatric patients undergoing oral chemotherapy during acute lymphoblastic leukaemia (ALL) maintenance therapy.

METHODS

English-speaking children, 4.0-17.99 years old and undergoing ALL maintenance treatment with an English-speaking guardian, were eligible to participate in this observational, serial, cross-sectional feasibility study. Data were collected from participants over one to three 7-day periods during months 2-3, 5-6 and 11-12 of ALL maintenance treatment. A future trial was considered feasible if the mean time to enrol 10 patients in each of three data collection periods was ≤1 year with ≥80% of patients returning evaluable data. CINV control was described as a secondary endpoint.

RESULTS

Twenty-nine of 31 consenting patients (median age: 6.5 years, IQR: 5.1-9.2) completed the study: 10 in months 2-3, 10 in months 5-6 and 9 in months 11-12. The total time to recruit 29 patients was 1.2 years. In each of the three data collections periods, 72% of the patients provided evaluable data. Complete CINV control was reported in 6/21 (29%) evaluable study periods.

CONCLUSIONS

A future trial to evaluate interventions to improve CINV control in patients with ALL undergoing oral maintenance chemotherapy as designed in this study is not feasible. An electronic data capture method and deferring patient recruitment until the mid-maintenance to late-maintenance phase should be considered in the design of a future trial.

摘要

目的

评估一项旨在改善接受口服化疗的小儿患者化疗所致恶心和呕吐(CINV)控制的大型前瞻性试验的可行性,这些患者处于急性淋巴细胞白血病(ALL)维持治疗中。

方法

符合条件的参与者为讲英语的 4.0-17.99 岁儿童,正在接受 ALL 维持治疗,有一位讲英语的监护人,他们可能参与这项观察性、连续、横断面可行性研究。在 ALL 维持治疗的第 2-3、5-6 和 11-12 个月期间,通过 1-3 个 7 天期收集参与者的数据。如果在每个数据收集期招募 10 名患者的平均时间≤1 年,且≥80%的患者返回可评估的数据,则认为未来的试验是可行的。CINV 控制被描述为次要终点。

结果

31 名同意参与的患者中有 29 名(中位数年龄:6.5 岁,IQR:5.1-9.2)完成了研究:10 名在第 2-3 个月,10 名在第 5-6 个月,9 名在第 11-12 个月。招募 29 名患者的总时间为 1.2 年。在每个数据收集期,有 72%的患者提供了可评估的数据。在 21 个可评估研究期中有 6 个(29%)报告了完全 CINV 控制。

结论

按照本研究设计,评估干预措施以改善接受口服维持化疗的 ALL 患者的 CINV 控制的未来试验是不可行的。在未来试验的设计中,应考虑采用电子数据捕获方法和将患者招募推迟到维持治疗的中期至晚期。

相似文献

1
Chemotherapy-induced nausea and vomiting from oral chemotherapy for childhood acute lymphoblastic leukaemia: feasibility study.化疗引起的口服化疗治疗儿童急性淋巴细胞白血病的恶心和呕吐:可行性研究。
BMJ Support Palliat Care. 2022 Nov;12(e5):e646-e649. doi: 10.1136/bmjspcare-2019-002022. Epub 2019 Nov 29.
2
Poor chemotherapy-induced nausea and vomiting control in children receiving intermediate or high dose methotrexate.接受中高剂量甲氨蝶呤治疗的儿童化疗引起的恶心和呕吐控制不佳。
Support Care Cancer. 2016 Mar;24(3):1365-71. doi: 10.1007/s00520-015-2924-1. Epub 2015 Sep 3.
3
Chemotherapy-induced nausea and vomiting control in pediatric patients receiving ifosfamide plus etoposide: a prospective, observational study.化疗诱导的恶心和呕吐控制在接受异环磷酰胺加依托泊苷的儿科患者中:一项前瞻性观察研究。
Support Care Cancer. 2020 Feb;28(2):933-938. doi: 10.1007/s00520-019-04903-0. Epub 2019 Jun 8.
4
Olanzapine for prevention of chemotherapy-induced nausea and vomiting in children and adolescents: a multi-center, feasibility study.奥氮平预防儿童和青少年化疗引起的恶心和呕吐:一项多中心可行性研究。
Support Care Cancer. 2018 Feb;26(2):549-555. doi: 10.1007/s00520-017-3864-8. Epub 2017 Aug 30.
5
Impact of adjuvant lorazepam with granisetron on chemotherapy-induced nausea and vomiting in pediatric patients with acute lymphoblastic leukemia.辅助劳拉西泮联合格拉司琼对急性淋巴细胞白血病患儿化疗诱导性恶心呕吐的影响。
Support Care Cancer. 2019 Mar;27(3):895-899. doi: 10.1007/s00520-018-4377-9. Epub 2018 Jul 31.
6
Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study.预测化疗相关恶心和呕吐的风险因素评估:一项欧洲前瞻性观察性研究的结果
J Pain Symptom Manage. 2014 May;47(5):839-848.e4. doi: 10.1016/j.jpainsymman.2013.06.012. Epub 2013 Sep 24.
7
Feasibility of using the Multinational Association of Supportive Care in Cancer Antiemesis Tool for assessment of chemotherapy-induced nausea and vomiting at the Tom Baker Cancer Centre.在汤姆·贝克癌症中心使用癌症支持性护理多国协会止吐工具评估化疗引起的恶心和呕吐的可行性。
J Oncol Pharm Pract. 2015 Oct;21(5):348-57. doi: 10.1177/1078155214540317. Epub 2014 Jun 17.
8
Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance).化疗引起的恶心和呕吐:持续症状的发生率、特征及未来方向 NCCTG N08C3(联盟)
Support Care Cancer. 2016 Jun;24(6):2661-7. doi: 10.1007/s00520-016-3080-y. Epub 2016 Jan 15.
9
Ondansetron versus granisetron in the prevention of chemotherapy induced nausea and vomiting in children with acute lymphoblastic leukemia.昂丹司琼与格拉司琼预防急性淋巴细胞白血病患儿化疗引起的恶心和呕吐的比较。
Mymensingh Med J. 2011 Oct;20(4):680-8.
10
Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.测试止吐指南的有效性:日本CINV研究组前瞻性登记研究结果
Int J Clin Oncol. 2015 Oct;20(5):855-65. doi: 10.1007/s10147-015-0786-7. Epub 2015 Feb 15.

引用本文的文献

1
Translation of the Pediatric Nausea Assessment Tool (PeNAT) Into Spanish and Evaluating Understandability Among Spanish-Speaking Hispanic American Children and Adolescents Receiving Chemotherapy.将儿科恶心评估工具(PeNAT)翻译成西班牙语,并评估接受化疗的讲西班牙语的西班牙裔美国儿童和青少年的理解能力。
Hisp Health Care Int. 2022 Mar;20(1):33-39. doi: 10.1177/15404153211003341. Epub 2021 Apr 15.